EA201291480A1 - Фактор ix полипептиды и способы их использования - Google Patents

Фактор ix полипептиды и способы их использования

Info

Publication number
EA201291480A1
EA201291480A1 EA201291480A EA201291480A EA201291480A1 EA 201291480 A1 EA201291480 A1 EA 201291480A1 EA 201291480 A EA201291480 A EA 201291480A EA 201291480 A EA201291480 A EA 201291480A EA 201291480 A1 EA201291480 A1 EA 201291480A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
factor
chimeric
hybrid polypeptides
polypeptides
Prior art date
Application number
EA201291480A
Other languages
English (en)
Other versions
EA028067B1 (ru
Inventor
Гленн Пирс
Саманта Трюкс
Роберт Т. Питерс
Хайянь Цзян
Original Assignee
Байоджен Айдек Хемофилия Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45441870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291480(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байоджен Айдек Хемофилия Инк. filed Critical Байоджен Айдек Хемофилия Инк.
Publication of EA201291480A1 publication Critical patent/EA201291480A1/ru
Publication of EA028067B1 publication Critical patent/EA028067B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

Настоящее изобретение предоставляет способы введения фактора IX; способы введения химерных и гибридных полипептидов, содержащих фактор IX; химерные и гибридные полипептиды, содержащие фактор IX; полинуклеотиды, кодирующие такие химерные и гибридные полипептиды; клетки, содержащие такие полинуклеотиды; и способы производства таких химерных и гибридных полипептидов с использованием таких клеток.
EA201291480A 2010-07-09 2011-07-11 Способы контроля или предотвращения кровотечения или эпизодов кровотечения EA028067B1 (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US36306410P 2010-07-09 2010-07-09
US61/363,064 2010-07-09
US201061424555P 2010-12-17 2010-12-17
US61/424,555 2010-12-17
US201161430819P 2011-01-07 2011-01-07
US61/430,819 2011-01-07
US201161438572P 2011-02-01 2011-02-01
US61/438,572 2011-02-01
US201161442079P 2011-02-11 2011-02-11
US61/442,079 2011-02-11
US201161470951P 2011-04-01 2011-04-01
US61/470,951 2011-04-01
PCT/US2011/043569 WO2012006624A2 (en) 2010-07-09 2011-07-11 Factor ix polypeptides and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201291480A1 true EA201291480A1 (ru) 2013-09-30
EA028067B1 EA028067B1 (ru) 2017-10-31

Family

ID=45441870

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201291480A EA028067B1 (ru) 2010-07-09 2011-07-11 Способы контроля или предотвращения кровотечения или эпизодов кровотечения
EA201790876A EA037095B1 (ru) 2010-07-09 2011-07-11 Способ лечения гемофилии в и эпизодов кровотечения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790876A EA037095B1 (ru) 2010-07-09 2011-07-11 Способ лечения гемофилии в и эпизодов кровотечения

Country Status (17)

Country Link
US (13) US9670475B2 (ru)
EP (2) EP2590668A4 (ru)
JP (5) JP2013534426A (ru)
KR (5) KR20180118808A (ru)
CN (1) CN103140237A (ru)
AU (5) AU2011274414B2 (ru)
BR (1) BR112013000650A8 (ru)
CA (1) CA2804274A1 (ru)
CL (1) CL2013000058A1 (ru)
EA (2) EA028067B1 (ru)
IL (3) IL223990B (ru)
MX (2) MX356527B (ru)
MY (2) MY192639A (ru)
NZ (1) NZ605348A (ru)
SG (3) SG10201505218YA (ru)
UA (2) UA126265C2 (ru)
WO (1) WO2012006624A2 (ru)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736339C1 (ru) * 2016-08-19 2020-11-16 Эмпсорс Биофарма Шанхай Инк. Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
US11471513B2 (en) 2016-08-19 2022-10-18 Ampsource Biopharma Shanghai Inc. Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
EP2470670A4 (en) 2009-08-24 2013-07-10 Amunix Operating Inc COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3590949T (pt) 2010-10-01 2022-08-02 Modernatx Inc Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG11201401196WA (en) 2011-10-03 2014-05-29 Moderna Therapeutics Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
CN104254614A (zh) * 2012-01-12 2014-12-31 比奥根艾迪克Ma公司 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
HUE046848T2 (hu) 2012-02-15 2020-03-30 Bioverativ Therapeutics Inc VIII. faktor készítmények és eljárások elõállításukra és alkalmazásukra
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
EP3505176A1 (en) 2012-04-02 2019-07-03 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP3521321B1 (en) 2012-04-11 2020-11-04 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN104519897A (zh) 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
TWI750197B (zh) * 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
US10391152B2 (en) 2012-10-18 2019-08-27 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
ES2744903T3 (es) * 2012-11-20 2020-02-26 Univ North Carolina Chapel Hill Métodos y composiciones para proteínas del factor IX modificadas
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
RS64664B1 (sr) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI745671B (zh) * 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3048899B1 (en) 2013-09-25 2021-09-08 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
JP2017500017A (ja) 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
RU2016129911A (ru) * 2013-12-23 2018-01-30 СиЭсЭл ЛИМИТЕД Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления
CA2943034C (en) * 2014-03-24 2022-06-14 Biogen Ma Inc. Lyophilized factor ix formulations
US11008561B2 (en) 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
JP6909203B2 (ja) * 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
EA201892347A1 (ru) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN109843319A (zh) 2016-07-08 2019-06-04 康诺贝林伦瑙有限公司 长效因子ix在人中的皮下施用
JP2020500874A (ja) 2016-12-02 2020-01-16 バイオベラティブ セラピューティクス インコーポレイテッド キメラ凝固因子を使用して血友病性関節症を処置する方法
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US11045128B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter for monitoring intra-abdominal pressure
US10799131B2 (en) 2017-06-03 2020-10-13 Sentinel Medical Technologies, LLC Catheter for monitoring intrauterine pressure to protect the fallopian tubes
US11185245B2 (en) 2017-06-03 2021-11-30 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure for muscle compartment syndrome
US10813589B2 (en) 2017-06-03 2020-10-27 Sentinel Medical Technologies, LLC Catheter for monitoring uterine contraction pressure
US11045143B2 (en) 2017-06-03 2021-06-29 Sentinel Medical Technologies, LLC Catheter with connectable hub for monitoring pressure
RU2020103424A (ru) 2017-06-29 2021-07-29 Цсл Беринг Ленгнау Аг Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
BR112020006149A2 (pt) 2017-09-27 2020-10-20 Sigilon Therapeutics, Inc. célula ativa manipulada, elemento implantável, e, composição farmacêutica.
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
EP3773517A1 (en) 2018-04-04 2021-02-17 Sigilon Therapeutics, Inc. Implantable particles and related methods
CN113227385A (zh) 2018-08-09 2021-08-06 比奥维拉迪维治疗股份有限公司 核酸分子及其用于非病毒基因疗法的用途
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
US11672457B2 (en) 2018-11-24 2023-06-13 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
US11779263B2 (en) 2019-02-08 2023-10-10 Sentinel Medical Technologies, Llc. Catheter for monitoring intra-abdominal pressure for assessing preeclampsia
EP3941509A1 (en) 2019-03-19 2022-01-26 CSL Behring Lengnau AG Factor ix variants and uses thereof in therapy
US20220323519A1 (en) 2019-04-17 2022-10-13 Codiak Biosciences, Inc. Compositions of exosomes and aav
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
EP4009860A4 (en) 2019-08-08 2022-11-16 Sentinel Medical Technologies, LLC CABLE FOR USE WITH PRESSURE MONITORING CATHETER
US11617543B2 (en) 2019-12-30 2023-04-04 Sentinel Medical Technologies, Llc. Catheter for monitoring pressure
WO2023275024A1 (en) * 2021-07-01 2023-01-05 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE145428T1 (de) 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
AU666388B2 (en) 1992-05-26 1996-02-08 Immunex Corporation Novel cytokine that binds CD30
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
CA2182498A1 (en) 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
EP0770135A1 (en) 1994-07-29 1997-05-02 Smithkline Beecham Plc Novel compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
EP0805628B1 (en) 1995-01-17 2003-05-02 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000007012A1 (en) 1998-07-31 2000-02-10 Carroll Wallace E Method and apparatus for determining anticoagulant therapy factors
ATE455552T1 (de) 1997-02-14 2010-02-15 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
AU2001252084B2 (en) 2000-04-28 2006-07-06 Inflazyme Pharmaceuticals Limited 3-nitrogen-6,7-dioxygen steroids and uses related thereto
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
CA2457429A1 (en) 2001-09-04 2003-03-13 Francis J. Carr Modified factor ix
PT2279755E (pt) 2001-10-10 2014-06-04 Ratiopharm Gmbh Remodelação e glicoconjugação do factor de crescimento de fibroblastos (fgf)
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CN1780637A (zh) * 2003-03-18 2006-05-31 诺和诺德医疗保健公司 因子ⅶ多肽类的含水液体药物组合物
US20050008580A1 (en) 2003-04-09 2005-01-13 Wyeth Hemophilia treatment by inhalation of coagulation factors
ES2361036T3 (es) 2003-05-06 2011-06-13 Syntonix Pharmaceuticals, Inc. Proteínas quiméricas vii-fc del factor de coagulación para el tratamiento de un trastorno hemostático.
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7212798B1 (en) * 2003-07-17 2007-05-01 Cisco Technology, Inc. Adaptive AGC in a wireless network receiver
JP2007501812A (ja) 2003-08-08 2007-02-01 ノボ　ノルディスク　アクティーゼルスカブ ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
AU2004296860B2 (en) 2003-12-03 2010-04-22 Novo Nordisk A/S Glycopegylated factor IX
DE602005021509D1 (de) 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1831363A1 (en) 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
US20060162552A1 (en) 2005-01-26 2006-07-27 Mohawk Valley Energy Solutions, Inc. Systems and methods for controlling room air quality
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
PL1942868T5 (pl) 2005-11-01 2023-12-27 Wyeth Llc Roztwór chlorku sodu do odtwarzania lub rozcieńczania leku
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007223888A1 (en) 2006-03-06 2007-09-13 Amunix, Inc. Genetic packages and uses thereof
EP2650305A1 (en) 2006-03-24 2013-10-16 Biogen Idec Hemophilia Inc. PC5 as a factor IX propeptide processing enzyme
PL2007885T3 (pl) * 2006-04-11 2010-12-31 Csl Behring Gmbh Sposób zwiększania odzysku peptydów terapeutycznych in vivo
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
PL3896090T3 (pl) * 2006-06-14 2022-05-02 Csl Behring Gmbh Rozszczepialne proteolitycznie białko fuzyjne zawierające czynnik krzepnięcia krwi
WO2007149406A2 (en) 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
JP5122562B2 (ja) 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
WO2008022151A1 (en) 2006-08-15 2008-02-21 Inspiration Biopharmaceuticals, Inc. Prophylactic treatment of hemophilia
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
WO2009051717A2 (en) 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
CA2721362A1 (en) 2008-04-16 2009-11-19 Bayer Healthcare Llc Site-directed modification of factor ix
AU2009244633A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified Factor IX polypeptides and uses thereof
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
MX2010011672A (es) * 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
US20090282865A1 (en) 2008-05-16 2009-11-19 Ortloff Engineers, Ltd. Liquefied Natural Gas and Hydrocarbon Gas Processing
WO2010020690A1 (en) 2008-08-21 2010-02-25 Octapharma Ag Recombinantly produced human factor viii and ix
BRPI0918988A2 (pt) 2008-09-24 2015-12-01 Stabilitech Ltd métodos para preservar um polipeptídeo e um imunógeno de vacina, e para preparar uma vacina, pó seco, produto preservado, frasco selado, ampola ou seringa, uso de um excipiente, e, vacina.
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
WO2011030641A1 (ja) 2009-09-08 2011-03-17 コニカミノルタホールディングス株式会社 身体用装具
MX2012004793A (es) 2009-10-30 2012-07-20 Novozymes Biopharma Dk As Variantes de albumina.
EP2353588B1 (en) 2010-01-21 2015-04-15 Agricultural Technology Research Institute A sustained release preparation of factor IX
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
CN103140237A (zh) 2010-07-09 2013-06-05 比奥根艾迪克依蒙菲利亚公司 因子ix多肽及其使用方法
US8822417B2 (en) 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
TWI750197B (zh) 2012-09-25 2021-12-21 美商百歐維拉提夫治療公司 Ｆｉｘ多肽的應用
EP3318124A3 (en) 2013-02-16 2018-05-30 Albumedix A/S Pharmacokinetic animal model
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
RU2016129911A (ru) 2013-12-23 2018-01-30 СиЭсЭл ЛИМИТЕД Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736339C1 (ru) * 2016-08-19 2020-11-16 Эмпсорс Биофарма Шанхай Инк. Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
RU2736339C9 (ru) * 2016-08-19 2021-05-28 Эмпсорс Биофарма Шанхай Инк. Слитый белок человеческого фактора свертывания IХ (FIX), способ его получения и применения
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
US11471513B2 (en) 2016-08-19 2022-10-18 Ampsource Biopharma Shanghai Inc. Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same
US11472863B2 (en) 2016-08-19 2022-10-18 Ampsource Biopharma Shanghai Inc. Human coagulation factor IX (FIX) fusion protein, preparation method therefor, and use thereof
US11833212B2 (en) 2016-08-19 2023-12-05 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein

Also Published As

Publication number Publication date
SG10201913700SA (en) 2020-03-30
AU2017268650B2 (en) 2019-10-10
US9629903B2 (en) 2017-04-25
US9233145B2 (en) 2016-01-12
AU2022204643A1 (en) 2022-07-21
MX2013000281A (es) 2013-03-22
SG10201505218YA (en) 2015-08-28
EA037095B1 (ru) 2021-02-05
AU2011274414B2 (en) 2016-10-06
NZ605348A (en) 2015-01-30
US20180207244A1 (en) 2018-07-26
EP2590668A2 (en) 2013-05-15
EA028067B1 (ru) 2017-10-31
US20160243206A1 (en) 2016-08-25
KR20190104442A (ko) 2019-09-09
US20130202595A1 (en) 2013-08-08
AU2020200118B2 (en) 2022-04-07
CA2804274A1 (en) 2012-01-12
AU2016228243A1 (en) 2016-10-06
JP2017036328A (ja) 2017-02-16
KR20220097518A (ko) 2022-07-07
IL277432B (en) 2021-07-29
WO2012006624A2 (en) 2012-01-12
MY192639A (en) 2022-08-29
US20160166657A1 (en) 2016-06-16
MX356527B (es) 2018-06-01
US20160346365A1 (en) 2016-12-01
AU2016228243B2 (en) 2017-08-31
AU2011274414A1 (en) 2013-01-24
US9867873B2 (en) 2018-01-16
US9670475B2 (en) 2017-06-06
EA201790876A1 (ru) 2017-12-29
JP2013534426A (ja) 2013-09-05
US9623091B2 (en) 2017-04-18
WO2012006624A3 (en) 2012-08-02
KR20230156435A (ko) 2023-11-14
KR20140017480A (ko) 2014-02-11
US10568943B2 (en) 2020-02-25
CN103140237A (zh) 2013-06-05
MX2020009702A (es) 2020-10-07
AU2017268650A1 (en) 2017-12-21
US20210008178A1 (en) 2021-01-14
JP2016034973A (ja) 2016-03-17
EP3552619A1 (en) 2019-10-16
US20190192641A1 (en) 2019-06-27
US20190192640A1 (en) 2019-06-27
CL2013000058A1 (es) 2014-03-28
US10561714B2 (en) 2020-02-18
EP2590668A4 (en) 2014-04-02
US20180228878A1 (en) 2018-08-16
US9675676B2 (en) 2017-06-13
JP2022044828A (ja) 2022-03-17
BR112013000650A2 (pt) 2016-05-31
IL284368A (en) 2021-07-29
JP2019023242A (ja) 2019-02-14
US20210023185A1 (en) 2021-01-28
KR20180118808A (ko) 2018-10-31
US20180228879A1 (en) 2018-08-16
AU2020200118A1 (en) 2020-01-30
MY166954A (en) 2018-07-25
US10548954B2 (en) 2020-02-04
IL277432A (en) 2020-11-30
IL223990B (en) 2020-10-29
US20130171175A1 (en) 2013-07-04
UA115120C2 (uk) 2017-09-25
US20160257943A1 (en) 2016-09-08
US10898554B1 (en) 2021-01-26
BR112013000650A8 (pt) 2017-10-17
UA126265C2 (uk) 2022-09-14
SG186856A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
EA201492101A1 (ru) Антитела против fcrn
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
UA109464C2 (ru) Спироксиндольные антагонисты mdm2
EA201400875A1 (ru) Антитела к cd47 и способы их применения
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201390993A1 (ru) Антитела к cd38
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
MY176820A (en) Egfr and c-met fibronectin type iii domain binding molecules
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
MY162737A (en) 4-1bb binding molecules
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
PH12014502182A1 (en) Methods and compositions for modulating notch activity
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent